Clinical Trial Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Increasing Pharmaceutical and Biotechnology R&D Expenditure

R&D budgets climbed 9.7% in 2024 among large drug makers, and pipelines now exceed 8,000 active assets, deepening demand for imaging endpoints that objectively track therapeutic impact. Biologics and gene therapies—expected to represent more than 60% of new approvals by 2030—often require molecular-level visualization, pushing sponsors to secure sophisticated imaging core lab support. Leading firms such as Eli Lilly have extended investments in GLP-1 programs, and each protocol embeds specialized MRI or PET components to monitor metabolic and cardiovascular parameters. As outsourcing grows, suppliers able to scale imaging services across continents stand out, with over 80% of R&D executives planning double-digit spending increases on external partners. This funding momentum anchors a long-term tailwind for the clinical trial imaging market.

Growing Outsourcing of Imaging Services to Contract Research Organizations

CRO revenues hit USD 52.19 billion in 2023, reflecting a strategic pivot by drug developers toward external imaging expertise to cut fixed costs and speed trial execution^{[1]ICON plc, “2024 Annual Report,” iconplc.com}. ICON alone reported USD 9.974 billion in new business wins during 2024, underscoring sponsor appetite for integrated imaging networks capable of protocol harmonization, real-time QC, and automated AI analytics. Outsourcing can trim study timelines by up to 30% by centralizing image data and applying predefined read algorithms, advantages magnified in hybrid and decentralized models that collect scans from community sites and patients’ homes. CROs are matching demand with targeted acquisitions in teleradiology, ophthalmic imaging, and quantitative biomarker platforms to widen service breadth across therapeutic areas.

Technological Advancements in Medical Imaging Modalities

Photon-counting CT scanners cut radiation dose while boosting spatial resolution, a breakthrough for longitudinal pediatric trials where cumulative exposure is a concern. PET-MRI hybrids deliver concurrent functional and anatomic data, simplifying patient visits and enhancing endpoint correlation in neuro-oncology programs. Portable MRI and low-payload CT units are extending trial reach to rural regions, broadening recruitment and supporting decentralized designs. Novel radiotracers, including PSMA agents for prostate cancer and FAPI compounds for fibrosis mapping, enrich biomarker toolkits and enable earlier treatment-response readouts^{[2]Journal of Nuclear Medicine, “Total-Body PET and Emerging Radiotracers,” jnm.snmjournals.org}. These innovations unlock new endpoints and improve data precision, reinforcing technology’s positive pull on the clinical trial imaging market.

Rising Adoption of Artificial Intelligence in Clinical Trial Imaging

More than half of healthcare organizations now deploy AI in at least one imaging workflow, compared with 17% in 2018. In trials, AI automates QC, flags protocol deviations, and extracts quantitative biomarkers in seconds, shrinking analysis bottlenecks and lowering inter-reader variability. ICON’s AI suite manages document routing, forecasts staffing needs, and supplies on-demand read analytics, while GE HealthCare’s acquisition of MIM Software brings deep-learning segmentation and dosimetry tools under one roof. Regulatory confidence is rising: the FDA lists more than 300 cleared AI imaging devices, and Europe has issued guidance on AI use in the product lifecycle^{[3]European Medicines Agency, “Clinical Trials Regulation,” ema.europa.eu}. Although most sponsors remain in pilot phases, growing confidence in validation frameworks signals rapid AI scale-up over the next two years.

High Capital Investment and Operational Costs of Imaging Equipment

State-of-the-art PET-MRI systems can cost USD 4-6 million, and photon-counting CT platforms add another USD 2-3 million burden before siting, shielding, and maintenance are factored in. Nuclear medicine programs require on-site radiopharmaceutical facilities that meet stringent cGMP standards, lifting total start-up spending far beyond many regional CROs or academic core labs. Rapid hardware cycles further complicate ROI calculations, pushing stakeholders toward mergers or strategic alliances, as seen in Affinity Equity Partners’ USD 658 million purchase of Lumus Imaging aimed at gaining scale economies.

Shortage of Skilled Imaging Professionals

Complex trial protocols depend on technologists, physicists, and image analysts versed in Good Clinical Practice, multi-modal acquisition, and regulatory submission standards. Despite growth initiatives, global supply trails demand, with vacancies highest in nuclear medicine and advanced MRI specialties. ICON employs more than 450 imaging experts, yet reports persistent recruitment strain in North America and Western Europe. Remote scanning supervision platforms and AI-guided acquisition workflows alleviate staffing gaps, but their deployment calls for regulatory approvals and secure data pathways, presenting an additional hurdle.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Clinical Trial Imaging Market Segment Analysis

Imaging software accounted for 31.85% of the clinical trial imaging market in 2025, cementing its status as the backbone of data flow across global sites. These platforms automate QC, anonymize datasets, and integrate seamlessly with electronic data capture systems, lowering error rates and ensuring consistency. In revenue terms, the segment formed the largest slice of the clinical trial imaging market size, and its influence will grow as AI modules move from pilot to production. The rise of SaaS deployment models is shifting budgets from capex to opex, appealing to small and mid-sized sponsors seeking scalability without heavy infrastructure outlay.

Imaging biomarker development services, meanwhile, are projected to expand at a 9.21% CAGR, reflecting escalating demand for validated, quantitative endpoints capable of persuading regulators and payers. Underpinning this surge are FDA initiatives that underscore the value of imaging biomarkers in accelerated approvals, and the movement toward personalized therapies that require sensitive measures of treatment response. Vendors that fuse software, biomarker science, and regulatory consulting are capturing higher-margin projects, intensifying competition in this growth pocket of the clinical trial imaging market.

Computed tomography held 24.70% of the clinical trial imaging market in 2025 thanks to its ubiquity, rapid acquisition times, and validated role in solid tumor trials. Its dominance also stems from reimbursement support and wide reader familiarity, factors essential to large phase III studies. Even so, the modality’s share is slowly eroding as sponsors pivot to lower-dose photon-counting systems and hybrid imaging that better resolve soft-tissue changes.

Positron emission tomography is expected to post a 9.29% CAGR through 2031, the fastest among modalities. Growth hinges on a pipeline of novel radiotracers that move beyond glucose metabolism to target cell-surface receptors, hypoxia markers, and amyloid aggregates. PET’s sensitivity in detecting molecular changes ahead of anatomical shifts makes it invaluable for early dose-response studies and adaptive trial designs. The spread of total-body PET scanners, which cut dose and bolster throughput, further sharpens its appeal and enlarges its role within the clinical trial imaging market.

Pharmaceutical and biotechnology sponsors generated 48.10% of clinical trial imaging market revenue in 2025 by directly funding core lab contracts, technology licenses, and equipment leases tied to their R&D portfolios. Their in-house imaging groups oversee protocol development and vendor management but increasingly partner with technology suppliers to integrate AI and cloud delivery. The expansion of GLP-1 and monoclonal antibody pipelines keeps imaging budgets robust, especially for metabolic, cardiovascular, and oncology programs.

Contract research organizations are the fastest-growing constituency, projected at an 10.78% CAGR through 2031. CROs absorb imaging responsibilities for small to mid-tier biotechs that lack internal expertise, and they offer global site networks, standardized SOPs, and consolidated data hubs. Strategic acquisitions—such as Clario’s purchase of NeuroRx—broaden therapeutic specialization and strengthen neurology capabilities, allowing CROs to capture emerging rare-disease opportunities poised to reshape the clinical trial imaging market.

Oncology contributed 32.05% of clinical trial imaging market revenue in 2025, cementing its primacy due to the modality-intensive nature of solid tumor assessments. RECIST metrics, bone lesion detection, and theranostic radiopharmaceuticals make imaging indispensable throughout oncology drug lifecycles. Immuno-oncology combinations and tissue-agnostic indications continue to propel imaging demand, with total-body PET and AI-assisted CT enabling earlier response readouts that inform mid-study dose adjustments.

Rare diseases, however, will outpace all other segments at a 9.93% CAGR because regulatory incentives and smaller patient pools magnify the utility of sensitive imaging biomarkers. NIH funding schemes encourage biomarker validation for conditions such as Friedreich’s ataxia and Huntington’s disease, prompting institutions like Biospective to develop sub-millimeter MRI protocols tailored to these populations. Precision endpoints derived from high-resolution neuroimaging reduce trial sizes and attenuate placebo effects, positioning this niche for outsized influence on the clinical trial imaging market.

Phase III programs consumed 40.95% of clinical trial imaging market outlays in 2025 because pivotal studies require global site harmonization, blinded independent central review, and rigorous archiving to satisfy regulators. These late-stage budgets accommodate multiple modalities, repeat scanning, and data locks synchronized to interim analyses, all of which inflate imaging spend. Sponsors also commission endpoint adjudication committees and duplicate reads to shore up data integrity ahead of marketing authorization submissions.

Phase I studies are forecast to register a 10.12% CAGR through 2031 as imaging biomarkers shift upstream to guide dose selection and patient stratification. Whole-organ perfusion MRI, dynamic contrast-enhanced CT, and molecular PET enable non-invasive quantification of early pharmacodynamic signals, reducing reliance on invasive biopsies. AI-driven image analysis accelerates read turnaround, allowing real-time dose-escalation decisions in adaptive study designs. Together, these developments will enlarge the proportion of early-phase resources devoted to imaging and bolster innovation across the clinical trial imaging market.

Geography Analysis

North America Clinical Trial Imaging Market

North America retained 38.10% of global revenue in 2025 on the strength of mature reimbursement systems, a dense network of academic-industrial partnerships, and clear FDA guidance governing imaging endpoints. The United States also hosts many of the top 20 pharma sponsors, amplifying domestic demand for high-throughput core labs that can scale across therapeutic franchises. Private-equity investments and acquisitions—RadNet spent USD 54 million on targets in 2024—are consolidating imaging capacity and integrating AI platforms, deepening the region’s competitive moat.

APAC Clinical Trial Imaging Market

Asia-Pacific is projected to deliver the highest regional CAGR at 8.55% through 2031, propelled by streamlined ethics approvals and attractive cost structures. Regulatory agencies in Japan, South Korea, and Singapore routinely finalize clinical trial applications within six months, shortening study start-up compared with legacy markets. Local CROs such as Wuxi AppTec have scaled imaging units that serve domestic and Western sponsors alike, leveraging broad site networks and government incentives to host multinational programs. The growing popularity of decentralized trials, tele-radiology, and bring-your-own-device imaging apps augments APAC’s role in the clinical trial imaging market.

Europe Clinical Trial Imaging Market

Europe sits between these poles as it transitions to the EU CTR, which mandates full use of the Clinical Trials Information System by January 2025. The unified portal promises consistent application reviews across 30 countries and should lower administrative overhead on cross-border imaging protocols. Yet divergent rules governing radiopharmaceutical handling and data privacy remain obstacles, particularly in Germany and France. Efforts by the EMA to publish an AI reflection paper and clarify validation expectations indicate that Europe aims to retain a leadership position in governance even as operational execution evolves.

Regulatory Landscape

Clinical trial imaging operations sit at the intersection of clinical trial GCP, data integrity requirements, and imaging-specific technical standards. In the United States, FDA guidance on Digital Health Technologies for remote data acquisition in clinical investigations (2024) raises the bar on fit-for-purpose validation. It emphasizes that digitally captured endpoints and associated workflows support interpretability for product evaluation, which affects decentralized imaging capture, QC, and audit readiness.

In Europe, the EU Clinical Trials Regulation (EU CTR) continues to harmonize trial authorization and oversight through the Clinical Trials Information System (CTIS). At the same time, the EMA maintains pathways for qualification of digital technology-based methodologies used in evidence generation. Imaging interoperability and documentation expectations are also being reinforced through standards activity, including ISO 12052:2026 (DICOM) published in February 2026 for imaging exchange and information management, and ISO 14155:2026 published in March 2026 updating GCP requirements for clinical investigations of medical devices. Separately, the US ONC issued a diagnostic imaging technical standards RFI in early 2026, signaling continued policy focus on interoperable imaging exchange and how trial imaging data can feed into broader certified health IT ecosystems.

Market Opportunities and Future Outlook

Operational whitespace is widening around making imaging data as traceable and inspection-ready as other clinical data streams under modern GCP expectations, including ICH E6(R3) interpretations that stress audit trails and contemporaneous oversight. That framing increases demand for platforms that unify image acquisition metadata, chain-of-custody, anonymization, and read outputs with clinical trial systems, rather than treating imaging as a parallel workflow. Providers that can package validated remote acquisition controls (aligned with FDA 2024 DHT guidance) with standardized DICOM-based data handling (ISO 12052:2026) have a clearer path to enterprise deployments across hybrid and decentralized trial designs.

AI-enabled response assessment and automated QC are also emerging as practical opportunities where workflow gains are already being tracked through literature and commercial product roadmaps. In May 2026, Medidata announced an enhanced AI-powered imaging capability within its Medidata Data Experience to automate image analysis and better integrate imaging outputs into trial data flows, reinforcing a platform-led buying pattern among sponsors and CROs. Academic work in 2026 also highlights performance improvements from fully automated CT deep-learning pipelines for earlier efficacy signal detection in simulated oncology trial settings, supporting continued investment in standardized, validated automation for RECIST and neuro-oncology response frameworks. At the same time, cross-jurisdiction requirements for AI software governance and data privacy are pushing vendors toward privacy-preserving and federated learning architectures that can scale model development without breaching data residency constraints.